Tag Archives: myl

Mylan Q4 Earnings, Guidance In Line As Growth Ramps

Generic-drug giant Mylan (MYL) late Monday reported Q4 earnings and 2015 guidance in line with Wall Street’s expectations, shortly after closing a major buyout. Mylan’s profit rose 35% over the year-earlier quarter to $1.05 a share, exactly as analysts expected, according to Thomson Reuters. Revenue gained 15% to $2.08 billion, slightly above consensus of $2.07 billion. Still, Mylan stock was down nearly 2% in after-hours trading Monday, after the

Mylan Makes Deals In Women’s Health, Lung Disease

Generic-drug giant Mylan (MYL) announced Monday that it’s buying $800 million in assets of an India-based women’s-health company. Mylan also bought into a lung-disease drug candidate. Mylan agreed to pay $750 million upfront plus up to $50 million in contingent payments for “certain female health care businesses” of Famy Care, with which Mylan has had a partnership since 2008. “This transaction especially complements Mylan’s pending acquisition of

Mylan Rises On Q3 Earnings Beat, Affirms Abbott Deal

Mylan (MYL) was up 3%, near 54, in early trading in the stock market today after the drugmaker beat Q3 estimates late Thursday. Earlier, the stock was up more than 7% at a nearly eight-month high above 56. Earnings came in on the high end of the raised guidance range that Mylan offered on Oct. 3, at $1.16 a share. That was up 41% from the year-earlier quarter and 2 cents higher than analysts’ consensus, according to Thomson Reuters. Sales rose 18%